6,880 Shares in Illumina, Inc. $ILMN Bought by Clear Harbor Asset Management LLC

Posted by Francis Steltz on Aug 23rd, 2026

Clear Harbor Asset Management LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 6,880 shares of the life sciences company’s stock, valued at approximately $1,210,000.

A number of other institutional investors also recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Illumina in the 2nd quarter valued at about $3,374,423,000. Plato Investment Management Ltd acquired a new stake in Illumina during the 2nd quarter worth approximately $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Illumina during the 2nd quarter worth approximately $30,501,000. Edmond DE Rothschild Holding S.A. acquired a new stake in Illumina during the 2nd quarter worth approximately $129,792,000. Finally, Impact Partnership Wealth LLC grew its stake in shares of Illumina by 235.8% in the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after purchasing an additional 7,780 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ILMN shares. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a report on Thursday, May 14th. Canaccord Genuity Group lifted their price objective on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. Stifel Nicolaus boosted their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $188.40.

Check Out Our Latest Report on Illumina

Insider Buying and Selling

In other Illumina news, SVP Christensen Jakob Wedel sold 1,033 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,095,958 shares of company stock valued at $401,720,974 over the last quarter. Company insiders own 2.90% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Stock Performance

NASDAQ ILMN opened at $219.40 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The business’s 50 day moving average is $188.01 and its two-hundred day moving average is $152.44. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $220.43. The stock has a market capitalization of $33.13 billion, a price-to-earnings ratio of 40.93, a PEG ratio of 3.09 and a beta of 1.45.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts expect that Illumina, Inc. will post 5.36 EPS for the current year.

Illumina Company Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.